Hoe Big Pharma de Medyske Oplieding Kontrôlearret
April 21, 2025 · Frisian News
Pharmaceutical companies spend billions funding medical schools, professorships, and student scholarships, shaping what doctors learn about drugs. Medical schools have become dependent on this money while maintaining the fiction of independence.
FryskIn medyske studint oan in grutte Nederlânske universiteit folget in kolleezje oer de behanneling fan hege bloeddruk. De professor dy't it materiaal presintearret, hâldt in learstuol dy't folslein troch in fabrikant fan bloedrukferlegende middels finansearre wurdt. De slides beklamje it produkt fan dit bedriuw boppe generyske alternativen. Nimmen yn it lokaal stelt fragen by dizze regeling, om't it normaal wurden is. It jild streamt yn stilte, en it medysk ûnderwiis feroaret dermei.
Farmaseutyske bedriuwen jouwe jierliks om en by 500 miljoen euro oan Europeeske medyske skoallen, ûndersykssintra en opliedingsprogramma's foar dokters. Se finansearje yndividuele learstuollen, beurzen en ferfolchkursussen. Genêsmiddelfabrikanten sponsorje ek de konferinsjes dêr't dokters gearkomme om nije behannelmetoaden te leare. Yn ruil dêrfoar krije se tagong ta jonge geasten tidens de meast foarmjende jierren fan 'e medyske oplieding. In studint dy't oer in medisyn leart fan in troch bedriuwen sponsore professor sil it letter as dokter wierskynliker foarskriuwe. De bedriuwen witte dit. Se hawwe berekkene hoe gau it jild weromkomt.
Medyske skoallen beweare ûnôfhinklik te wêzen fan yndustrybydragen, mar se kinne net funksjonearje sûnder it jild. Universiteiten besunigje op de begrutting foar basisûndersyk, wylst farmaseutyske finansiering it gat opfolt. Professoren akseptearje yndustrjedonaasjes om har wurk te stypjen. Studinten krije beurzen sûnder betingsten, of sa stelle de skoallen it foar. It resultaat is in systeem wêryn farmajild de hiele struktuer fan medyske oplieding stipet. Nim it fuort, en in protte skoallen soene muoite hawwe om de ljochten brânde te hâlden. Gjin inkele ynstelling yn dizze posysje kin echt de hân bite dy't har fiedt.
De belangekonflikten geane djipper as de measte pasjinten begripe. In dokter dy't syn oplieding krige fan professoren dy't troch bedriuwen finansearre wurde, learret djoere merkgenêsmiddels as standertsoarch te sjen. Underwiis oer betelbere generyske middels of behannelmetoaden sûnder medisinen kriget minder oandacht en minder finansiering. Medyske skoallen produsearje ôfstudearden dy't automatysk nei de meast winstjouwende medisinen gripe, net altyd de meast passende. Dit is gjin komplot dat yn direksjekeamers smeid wurdt. It is in systeem dat himsels beleant en himsels fuortplantet oer generaasjes dokters.
Guon medyske skoallen yn Skandinavië en dielen fan Switserlân hawwe de beheiningen op farmaseutyske sponsoring oanskerpet. Se fûnen oare finansieringsboarnen en behâlden de akademyske frijheid. Mar de measte Europeeske universiteiten hawwe dizze kar net makke. Se jouwe de foarkar oan it jild. Oant medyske skoallen net mear ôfhinklik binne fan farmajild, bliuwe dokters genêskunde leare fan professoren mei belangekonflikten. De pasjinten binne dejingen dy't de priis betelje.
A medical student at a major Dutch university attends a lecture on hypertension treatment. The professor presenting the material holds a research chair funded entirely by a manufacturer of blood pressure drugs. The slides emphasize this company's product over generic alternatives. No one in the room questions this arrangement, because it has become normal. The money flows in quietly, and medical education shifts with it.
Pharmaceutical firms donate roughly 500 million euros annually to European medical schools, research centers, and doctor training programs. They fund individual professorships, scholarships, and continuing education courses. Drug companies also sponsor the conferences where doctors gather to learn new treatment methods. In return, they gain access to young minds during the most formative years of medical training. A student who learns about a drug from a company-sponsored professor is more likely to prescribe it later as a doctor. The companies know this. They have calculated the return on investment.
Medical schools claim independence from industry influence, yet they cannot function without the money. Universities cut budgets for basic research while pharmaceutical funding fills the gap. Professors accept industry donations to support their work. Students receive scholarships with no strings attached, or so the schools insist. The result is a system where pharma money props up the entire structure of medical education. Remove it, and many schools would struggle to keep the lights on. No institution in this position can truly bite the hand that feeds it.
The conflicts of interest run deeper than most patients understand. A doctor trained by industry-sponsored professors learns to see expensive patented drugs as standard care. Teaching about cost-effective generics or non-drug treatments gets less attention and less funding. Medical schools produce graduates who reflexively reach for the most profitable medications, not always the most appropriate ones. This is not a conspiracy hatched in boardrooms. It is a system that rewards itself and reproduces itself across generations of doctors.
Some medical schools in Scandinavia and parts of Switzerland have tightened restrictions on pharmaceutical sponsorship. They found other funding sources and maintained academic freedom. But most European universities have not made this choice. They prefer the money. Until medical schools stop depending on drug company cash, doctors will continue to learn medicine from professors with conflicts of interest. The patients are the ones who pay the price.
Published April 21, 2025 · Frisian News · Ljouwert, Fryslân